Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15056281 | 0.85 | KDM4E (0.46) | HCAR2KDM4EPOLBPDE4DMAPT | |
| Hydrochloric Acid SCHEMBL15056842 | 0.84 | KDM4E (0.44) | HCAR2KDM4EPOLBPDE4DMAPT | |
| SCHEMBL24906430 | 0.82 | KDM4E (0.43) | HCAR2KDM4EPOLBPDE4DMAPT | |
| SCHEMBL28835673 | 0.82 | KDM4E (0.43) | HCAR2KDM4EPOLBPDE4DMAPT | |
| SCHEMBL30130665 | 0.79 | KDM4E (0.41) | HCAR2KDM4EPOLBPDE4DMAPT | |
| SCHEMBL24877924 | 0.78 | KDM4E (0.43) | HCAR2KDM4EPOLBPDE4DMAPT | |
| SCHEMBL679590 | 0.78 | KDM4E (0.43) | HCAR2KDM4EPOLBPDE4DMAPT | |
| SCHEMBL3945902 | 0.78 | HCAR2 (0.59) | HCAR2KDM4EPOLBPDE4DMTOR | |
| SCHEMBL28693887 | 0.78 | KDM4E (0.50) | HCAR2KDM4EPOLBPDE4DMTOR | |
| SCHEMBL1412595 | 0.77 | KDM4E (0.43) | KDM4EPOLBPDE4DMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551403-B1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | ARENA PHARM INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20060167270-A1 | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia | ARENA PHARMACEUTICALS INC. (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1551403-A1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004032928-A1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | ARENA PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167270-A1 | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia | ACE, ACE2, AGTR2 | HCAR2 30/4885KDM4E 2712/4885POLB 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.